RIVA-PAROXETINE TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE)

から入手可能:

LABORATOIRE RIVA INC.

ATCコード:

N06AB05

INN（国際名）:

PAROXETINE

投薬量:

20MG

医薬品形態:

TABLET

構図:

PAROXETINE (PAROXETINE HYDROCHLORIDE HEMIHYDRATE) 20MG

投与経路:

ORAL

パッケージ内のユニット:

100/500

処方タイプ:

Prescription

治療領域:

SELECTIVE-SEROTONIN REUPTAKE INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0123131002; AHFS:

認証ステータス:

APPROVED

承認日:

2004-01-09

製品の特徴

_Page 1 of 56_
_RIVA-PAROXETINE – Product Monograph_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
RIVA-PAROXETINE
Paroxetine Tablets
Tablets, 10 mg, 20 mg and 30 mg paroxetine (as paroxetine
hydrochloride hemihydrate), Oral
USP
Selective Serotonin Reuptake Inhibitor
LABORATOIRE RIVA INC.
660 Boul. Industriel
Blainville, Quebec
J7C 3V4
www.labriva.com
Submission Control No.: 276263
Date of Initial Authorization:
JAN
9, 2004
Date of Revision:
JUL 10, 2023
_RIVA-PAROXETINE – Product Monograph _
_Page 2 of 56_
RECENT MAJOR LABEL CHANGES
SECTION
DATE
7 WARNINGS AND PRECAUTIONS, Cardiovascular
7 WARNINGS AND PRECAUTIONS, Hematologic
07/2022
7 WARNINGS AND PRECAUTIONS, Immune
05/2021
7 WARNINGS AND PRECAUTIONS, Neurologic
07/2022
7 WARNINGS AND PRECAUTIONS, Psychiatric
7 WARNINGS AND PRECAUTIONS, Reproductive Health: Female and
Male Potential
05/2021
7 WARNINGS AND PRECAUTIONS, 7.1.1 Pregnant Women
07/2022
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
2
1
INDICATIONS
..............................................................................................................
4
1.1
Pediatrics
...................................................................................................................
4
1.2
Geriatrics
...................................................................................................................
4
2
CONTRAINDICATIONS
.................................................................................................
5
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 5
4
DOSAGE AND ADMINISTRATI